Last updated: September 2021

Prescription under medical supervision

Therapeutic action

– Antiretroviral, HIV nucleoside reverse transcriptase inhibitor 


– HIV infection, in combination with other antiretroviral drugs

Forms and strengths

– 300 mg tablet


– Adult: 300 mg 2 times daily or 600 mg once daily


– Depending on the efficacy and tolerance of abacavir.

Contra-indications, adverse effects, precautions

– Do not administer to patients with severe hepatic impairment or history of hypersensibility reaction to abacavir that led to discontinuation of treatment.
– Administer with caution to patients with hypertension, diabetes, hyperlipidemia (might increase the risk of coronary disease).
– May cause:
• hypersensitivity reactions: fever, rash, gastrointestinal disturbances (nausea, vomiting, diarrhoea, abdominal pain), pharyngitis, cough, dyspnoea, malaise, headache, lethargy, myalgia, arthralgia;
• lactic acidosis, pancreatitis and hepatic disorders.
In all these cases, stop taking abacavir immediately and permanently.
Pregnancy: no contra-indication


– Also comes in fixed-dose combinations (abacavir 120 mg/lamivudine 60 mg dispersible, breakable, paediatric tablet and abacavir 600 mg/lamivudine 300 mg tablet). Preferably use these formulations when available.
Storage: below 25 °C -  -